Get the Stockscreener App
73.94
1.23%
0.90
Henry Schein Inc stock is traded at $73.94, with a volume of 1.20M.
It is up +1.23% in the last 24 hours and down -9.13% over the past month.
Henry Schein Inc is a solutions company for healthcare professionals. It offers healthcare equipment, products, and services to office-based dental and medical practitioners, as well as alternative sites of care. The company's reportable segments are: Global Distribution and Value-Added Services, Global Specialty Products, and Global Technology. It generates maximum revenue from the Global Distribution and Value-Added Services segment, which includes distribution to the dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services. This segment also includes value-added services such as financial services, continuing education services, consulting, and other practice services.
See More
Previous Close:
$73.04
Open:
$72.74
24h Volume:
1.20M
Relative Volume:
0.90
Market Cap:
$8.48B
Revenue:
$13.18B
Net Income/Loss:
$419.00M
P/E Ratio:
22.61
EPS:
3.2704
Net Cash Flow:
$521.00M
1W Performance:
+0.31%
1M Performance:
-9.13%
6M Performance:
+11.98%
1Y Performance:
+6.77%
1-Day Range:
$71.31
$75.10
1-Week Range:
$71.31
$75.10
52-Week Range:
$60.56
$89.29
Henry Schein Inc Stock (HSIC) Company Profile
Name
Henry Schein Inc
Sector
Industry
Phone
(631) 843-5500
Address
135 DURYEA RD, MELVILLE, NY
Compare HSIC vs MCK, COR, CAH, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HSIC
Henry Schein Inc
|
73.94 | 8.48B | 13.18B | 419.00M | 521.00M | 3.2704 |
MCK
Mckesson Corporation
|
884.28 | 108.31B | 397.96B | 4.55B | 9.64B | 34.77 |
COR
Cencora Inc
|
324.80 | 63.18B | 325.78B | 1.64B | 3.61B | 8.3139 |
CAH
Cardinal Health Inc
|
214.05 | 50.37B | 244.67B | 1.68B | 5.51B | 6.9487 |
AHG
Akso Health Group Adr
|
2.22 | 1.90B | 14.85M | -136.07M | 7.23M | -0.4726 |
Henry Schein Inc Stock (HSIC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-23-26 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Aug-26-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Jul-25-25 | Downgrade | Stifel | Buy → Hold |
| Jul-14-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Feb-14-25 | Initiated | Wells Fargo | Equal Weight |
| Jan-06-25 | Upgrade | BofA Securities | Underperform → Buy |
| Dec-04-24 | Initiated | Mizuho | Neutral |
| Jul-22-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-12-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Nov-10-23 | Upgrade | Stifel | Hold → Buy |
| Aug-08-22 | Upgrade | UBS | Sell → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Neutral |
| Jun-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| Jan-31-22 | Initiated | Morgan Stanley | Underweight |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Oct-01-21 | Resumed | Credit Suisse | Neutral |
| Feb-08-21 | Resumed | Piper Sandler | Overweight |
| Jan-04-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-03-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Apr-07-20 | Upgrade | Goldman | Neutral → Buy |
| Apr-02-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jan-09-20 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-02-20 | Upgrade | Evercore ISI | Underperform → In-line |
| Aug-07-19 | Downgrade | William Blair | Outperform → Mkt Perform |
| May-30-19 | Initiated | Wolfe Research | Underperform |
| May-15-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-18-19 | Initiated | Guggenheim | Buy |
| Jan-17-19 | Initiated | UBS | Sell |
| Jan-03-19 | Downgrade | Evercore ISI | In-line → Underperform |
| Jan-02-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Nov-08-18 | Reiterated | Barrington Research | Outperform |
| Oct-25-18 | Downgrade | Edward Jones | Hold → Sell |
| Oct-19-18 | Resumed | Goldman | Neutral |
| Oct-04-18 | Reiterated | Robert W. Baird | Outperform |
| Aug-07-18 | Reiterated | Stifel | Hold |
| Apr-24-18 | Downgrade | Goldman | Buy → Neutral |
| Apr-04-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
View All
Henry Schein Inc Stock (HSIC) Latest News
Henry Schein Inc. stock outperforms competitors on strong trading day - MarketWatch
Entry Recap: Is Henry Schein Inc still a buy after recent gainsTrade Ideas & Low Risk Entry Point Tips - baoquankhu1.vn
Henry Schein (HSIC) price target increased by 12.37% to 90.80 - MSN
Henry Schein (HSIC) down 9.4% since last earnings report: Can it rebound? - MSN
Henry Schein Inc. stock rises Tuesday, still underperforms market - MarketWatch
Henry Schein Inc Stock: A Steady Force in Dental and Medical Distribution for North American Investo - AD HOC NEWS
Why Henry Schein (HSIC) is a Top Value Stock for the Long-Term - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Encompass Health (EHC) and Merck & Company (MRK) - The Globe and Mail
Henry Schein: A Cash-Generating Healthcare Distributor Priced for Mediocrity - TradingView
Henry Schein, Inc. (NASDAQ:HSIC) Short Interest Update - MarketBeat
Assenagon Asset Management S.A. Buys 45,701 Shares of Henry Schein, Inc. $HSIC - MarketBeat
Henry Schein stock drops 2.18% as company recognized among World’s Most Ethical Companies - Traders Union
Henry Schein Inc Stock: A Steady Force in Dental and Medical Distribution for Long-Term Investors - AD HOC NEWS
Henry Schein stock hits 52-week highhere's why - msn.com
Henry Schein Inc. stock underperforms Friday when compared to competitors - MarketWatch
Vanguard Reports 0 Shares in Henry Schein After Realignment (NASDAQ: HSIC) - stocktitan.net
Henry Schein One Drives Growth with Cloud-Based Dental Solutions and AI Integration - Bitget
Henry Schein (HSIC) Down 9.4% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Should You Keep Henry Schein Shares in Your Investment Portfolio at This Time? - Bitget
Should You Retain Henry Schein Stock in Your Portfolio for Now? - Yahoo Finance
Henry Schein (HSIC) Goldman Sachs 45th Annual Global Healthcare Conference Summary - Quartr
How Surging Global Specialty Sales At Henry Schein (HSIC) Have Changed Its Investment Story - Yahoo Finance
Henry Schein, Inc. $HSIC Shares Purchased by SG Americas Securities LLC - MarketBeat
Henry Schein, Vir Biotechnology, Ultra Clean Holdings and other big stocks moving higher on Tuesday - MSN
Henry Schein stock faces uncertain trading amid lack of fresh catalysts in dental distribution secto - AD HOC NEWS
Is Henry Schein Stock Underperforming the S&P 500? - Barchart
This Henry Schein analyst turns bullish; here are top 3 upgrades for Monday - MSN
Push Button Handpiece Conversion Midwest 380420 Low Speed AdapterHenry Schein Dental Push Button Starter Kit - hotelier.com.py
Tudor Investment Corp ET AL Invests $15.38 Million in Henry Schein, Inc. $HSIC - MarketBeat
Henry Schein Q4 2025 earnings preview - MSN
Decliners Report: Will Henry Schein Inc face regulatory challengesWeekly Market Summary & Growth Oriented Trading Recommendations - baoquankhu1.vn
Barclays Sticks to Their Buy Rating for Henry Schein (HSIC) - The Globe and Mail
Top Henry Schein Executive Makes Notable Insider Stock Move - TipRanks
Henry Schein (NASDAQ:HSIC) CEO Thomas Popeck Sells 1,355 Shares - MarketBeat
Insider Sell: Thomas Popeck Sells Shares of Henry Schein Inc (HS - GuruFocus
Charisma 66000085 Universal CompositeHenry Schein Dental - hotelier.com.py
Henry Schein CEO Popeck sells $98,630 in stock - Investing.com
Henry Schein CEO Popeck sells $98,630 in stock By Investing.com - Investing.com Australia
Henry Schein (HSIC) products CEO sells 1,355 shares in open-market trade - Stock Titan
3M Scotchbond 7423 Etchant Etching GelHenry Schein Dental - hotelier.com.py
Here's why Henry Schein (HSIC) is a strong growth stock - MSN
HSIC (NASDAQ) Form 144: insiders list 144, 191, 1,020 shares tied to vesting - Stock Titan
Zacks Research Has Negative View of Henry Schein Q1 Earnings - MarketBeat
Here's why Henry Schein (HSIC) is a strong value stock - MSN
Henry Schein Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Henry Schein secures Ethisphere World Most Ethical Companies recognition for 15th consecutive year - Traders Union
Henry Schein Named Among World’s Most Ethical Companies - Dentistry Today
Ethisphere Names Henry Schein as One of the 2026 World's Most Ethical Companies(R) for 15th Consecutive Year - MarketScreener
Here's Why Henry Schein (HSIC) is a Strong Growth Stock - Yahoo Finance
Henry Schein Inc Stock (HSIC) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.31%
6.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):